Clinical Trial Update: A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study evaluating the efficacy and safety of SB-742457 (idalopirdine) in Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SB-742457

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED